CA3021788C - Use of nalmefene in non-alcoholic steatohepatitis - Google Patents

Use of nalmefene in non-alcoholic steatohepatitis Download PDF

Info

Publication number
CA3021788C
CA3021788C CA3021788A CA3021788A CA3021788C CA 3021788 C CA3021788 C CA 3021788C CA 3021788 A CA3021788 A CA 3021788A CA 3021788 A CA3021788 A CA 3021788A CA 3021788 C CA3021788 C CA 3021788C
Authority
CA
Canada
Prior art keywords
compound
alcoholic
nash
alcoholic steatohepatitis
liver
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3021788A
Other languages
English (en)
French (fr)
Other versions
CA3021788A1 (en
Inventor
Edwin Sc Wu
Peter J.S. Chiu
May Mei-Chi Hsu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
TaiwanJ Pharmaceuticals Co Ltd
Original Assignee
TaiwanJ Pharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by TaiwanJ Pharmaceuticals Co Ltd filed Critical TaiwanJ Pharmaceuticals Co Ltd
Publication of CA3021788A1 publication Critical patent/CA3021788A1/en
Application granted granted Critical
Publication of CA3021788C publication Critical patent/CA3021788C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA3021788A 2016-04-22 2017-04-20 Use of nalmefene in non-alcoholic steatohepatitis Active CA3021788C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662326435P 2016-04-22 2016-04-22
US62/326,435 2016-04-22
US201662395436P 2016-09-16 2016-09-16
US62/395,436 2016-09-16
PCT/US2017/028529 WO2017184819A1 (en) 2016-04-22 2017-04-20 Nalmefene, naltrexone or derivatives thereof for use in treating (non)-alcoholic steatohepatitis or non-alcoholic fatty liver disease

Publications (2)

Publication Number Publication Date
CA3021788A1 CA3021788A1 (en) 2017-10-26
CA3021788C true CA3021788C (en) 2021-08-03

Family

ID=58668969

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3021788A Active CA3021788C (en) 2016-04-22 2017-04-20 Use of nalmefene in non-alcoholic steatohepatitis

Country Status (10)

Country Link
US (1) US10045977B2 (https=)
EP (1) EP3445363A1 (https=)
JP (1) JP2019514872A (https=)
KR (1) KR20180129909A (https=)
CN (2) CN117137917A (https=)
AU (1) AU2017253228B2 (https=)
BR (1) BR112018071705A2 (https=)
CA (1) CA3021788C (https=)
RU (1) RU2717677C1 (https=)
WO (1) WO2017184819A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9719068B2 (en) 2010-05-06 2017-08-01 Children's Hospital Medical Center Methods and systems for converting precursor cells into intestinal tissues through directed differentiation
CN106661548B (zh) 2014-05-28 2020-12-11 儿童医院医疗中心 用于经由定向分化将前体细胞转化为胃组织的方法和系统
JP6804438B2 (ja) 2014-10-17 2020-12-23 チルドレンズ ホスピタル メディカル センター 多能性幹細胞を使用するヒト小腸のｉｎ ｖｉｖｏモデル、並びにそれを作製、及び使用する方法
ES2929758T3 (es) 2016-05-05 2022-12-01 Childrens Hospital Med Ct Métodos para la fabricación in vitro de tejido del fondo gástrico y composiciones relacionadas con el mismo
CN109475626A (zh) * 2016-07-14 2019-03-15 儿童医院医疗中心 治疗纤维化的方法
KR102729404B1 (ko) 2016-11-04 2024-11-14 칠드런즈 호스피탈 메디칼 센터 간 유사 장기 조성물 및 이를 제조 및 사용하는 방법
JP7068305B2 (ja) 2016-12-05 2022-05-16 チルドレンズ ホスピタル メディカル センター 結腸オルガノイドならびにその作製方法および使用方法
US12281334B2 (en) 2017-04-14 2025-04-22 Children's Hospital Medical Center Multi donor stem cell compositions and methods of making same
EP3694603B1 (en) 2017-10-10 2026-04-08 Children's Hospital Medical Center Esophageal tissue and/or organoid compositions and methods of making same
US12379372B2 (en) 2017-12-21 2025-08-05 Children's Hospital Medical Center Digitalized human organoids and methods of using same
KR102887406B1 (ko) 2018-07-26 2025-11-19 칠드런즈 호스피탈 메디칼 센터 간-담도-췌장 조직 및 이를 제조하는 방법
AU2019339410A1 (en) 2018-09-12 2021-04-15 Children's Hospital Medical Center Organoid compositions for the production of hematopoietic stem cells and derivatives thereof
WO2020160371A1 (en) 2019-02-01 2020-08-06 The University Of Hong Kong Innervated organoid compositions and methods of making same
WO2020243633A1 (en) 2019-05-31 2020-12-03 Children's Hospital Medical Center Shaped organoid compositions and methods of making same
WO2020243613A1 (en) 2019-05-31 2020-12-03 Children's Hospital Medical Center Methods of generating and expanding hematopoietic stem cells
CA3236690A1 (en) 2021-11-18 2023-05-25 Ju Hee Kim Sustained-release injectable composition containing naltrexone and method for preparing same
EP4413977A4 (en) 2021-11-18 2025-11-05 Inventage Lab Inc METHOD FOR PREPARING MICROPARTICLES CONTAINING LOWLY SOLUBLE MEDICINES

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5086058A (en) * 1990-06-04 1992-02-04 Alko Ltd. Method for treating alcoholism with nalmefene
US7923454B2 (en) 2002-05-17 2011-04-12 Jenken Biosciences, Inc. Opioid and opioid-like compounds and uses thereof
EP2987788A1 (en) 2002-05-17 2016-02-24 Taiwanj Pharmaceuticals Co., Ltd. Opioid and opioid-like compounds and uses thereof
US8017622B2 (en) * 2003-05-16 2011-09-13 Jenken Biosciences, Inc. Opioid and opioid-like compounds and uses thereof
US10363251B2 (en) * 2009-07-16 2019-07-30 Mallinckrodt Llc (+)-morphinans as antagonists of toll-like receptor 9 and therapeutic uses thereof
TR201002473A2 (tr) * 2010-03-31 2011-09-21 Mustafa Nevzat �La� Sanay�� A.�. Herpes zoster hastalığının bır opiat reseptör antagonist kullanılarak tedavi yöntemi.
CN102048733B (zh) * 2010-12-23 2011-12-28 武汉同源药业有限公司 盐酸纳美芬在制备治疗脂肪肝的药物中的用途
IN2013MU01468A (https=) * 2013-04-22 2015-04-17 Cadila Healthcare Ltd
EP3939570A1 (en) * 2016-02-18 2022-01-19 Immune Therapeutics, Inc. Naltrexone for treating or preventing autoimmune and inflammatory diseases

Also Published As

Publication number Publication date
CN109069503A (zh) 2018-12-21
AU2017253228A8 (en) 2019-01-17
AU2017253228B2 (en) 2020-04-09
CN117137917A (zh) 2023-12-01
US20170304294A1 (en) 2017-10-26
WO2017184819A1 (en) 2017-10-26
RU2717677C1 (ru) 2020-03-25
JP2019514872A (ja) 2019-06-06
KR20180129909A (ko) 2018-12-05
BR112018071705A2 (pt) 2019-02-19
AU2017253228A1 (en) 2018-09-27
CA3021788A1 (en) 2017-10-26
EP3445363A1 (en) 2019-02-27
US10045977B2 (en) 2018-08-14

Similar Documents

Publication Publication Date Title
CA3021788C (en) Use of nalmefene in non-alcoholic steatohepatitis
JP2019514872A5 (https=)
AU2020267217B2 (en) Therapeutic methods employing noribogaine and related compounds
CN110638805A (zh) 促进吸烟停止
CN106999467A (zh) 治疗认知减退的方法
CN107951869A (zh) 含有大麻二酚的药物制剂及其应用
Hu et al. Effect of Piper nigrum essential oil in dextran sulfate sodium (DSS)-induced colitis and its potential mechanisms
KR101558476B1 (ko) 필버톤의 신규한 용도
US20150306167A1 (en) Alpinia spp. extracts for treating irritable bowel syndrome
JP7759109B2 (ja) Ｅｏｍｅｓ陽性ＣＤ４陽性Ｔ細胞の増加に起因する進行型疾患治療剤
US20180318290A1 (en) Use of nalmefene in non-alcoholic steatohepatitis
CN114555577A (zh) 用于治疗门静脉炎症和纤维化的噻吩衍生物
JP2019041675A (ja) Ｎａｓｈ肝発がんモデル非ヒト動物及びその使用
TW201813646A (zh) 納美芬(nalmefene)在非酒精性脂肪肝炎(nash)的應用
CN113368107B (zh) 包含小檗碱和苦参碱的药物组合物及其治疗或预防非酒精性脂肪性肝病的用途
CN100340246C (zh) 一种河鲀油制剂及其制备方法
CN106632378A (zh) 一种可抑制肥大细胞脱颗粒的化合物及其制备方法和用途
CN101224212A (zh) 阿魏酸及其钠盐用于制备预防和治疗抑郁症的药物
CN112972440A (zh) 麝香酮在制备防治抑郁症的药物中的用途
US20240058300A1 (en) Tocotrienol compositions and methods to treat non-alcoholic steatohepatitis
KR20190130241A (ko) 크로몰린 또는 이의 약학적으로 허용가능한 염을 유효성분으로 함유하는 지방간의 예방 또는 치료용 약학적 조성물
CN105902527A (zh) 一种具有降低血糖作用的药物组合物及其制备方法和应用
KR101541016B1 (ko) 피노카베올의 신규한 용도
WO2022246586A1 (en) Use of a curcuminoid-rich oil extract for treating acute lung injury
WO2016152965A1 (ja) 低アルブミン血症の改善剤

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20181019

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 8TH ANNIV.) - STANDARD

Year of fee payment: 8

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250327

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250327

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250327

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 9TH ANNIV.) - STANDARD

Year of fee payment: 9

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260416

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260416